ECSP055912A - Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas - Google Patents
Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetasInfo
- Publication number
- ECSP055912A ECSP055912A EC2005005912A ECSP055912A ECSP055912A EC SP055912 A ECSP055912 A EC SP055912A EC 2005005912 A EC2005005912 A EC 2005005912A EC SP055912 A ECSP055912 A EC SP055912A EC SP055912 A ECSP055912 A EC SP055912A
- Authority
- EC
- Ecuador
- Prior art keywords
- diffosphate
- aminocarbonil
- adenosine
- antagonists
- receptor
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 abstract 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Los compuestos de la fórmula (I), donde m, n, R1, R2, R3, R4 y R6 tienen los valores que se definen en la memoria descriptiva, son útiles como inhibidores del difosfato de adenosina plaquetario. También se describen composiciones farmacéuticas que contienen estos compuestos, los métodos para usar estos compuestos como agentes antitrombóticos y los procesos para sintetizar estos compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43279202P | 2002-12-11 | 2002-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055912A true ECSP055912A (es) | 2005-11-22 |
Family
ID=32507994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005912A ECSP055912A (es) | 2002-12-11 | 2005-07-11 | Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas |
Country Status (23)
Country | Link |
---|---|
US (2) | US7056923B2 (es) |
EP (1) | EP1578423B1 (es) |
JP (1) | JP4662777B2 (es) |
KR (1) | KR20050085580A (es) |
CN (1) | CN1747732A (es) |
AP (1) | AP2005003363A0 (es) |
AT (1) | ATE477800T1 (es) |
AU (1) | AU2003297763A1 (es) |
BR (1) | BR0317222A (es) |
CA (1) | CA2507657C (es) |
DE (1) | DE60333866D1 (es) |
EA (1) | EA200500899A1 (es) |
EC (1) | ECSP055912A (es) |
ES (1) | ES2348942T3 (es) |
MX (1) | MXPA05006302A (es) |
NO (1) | NO20053335L (es) |
NZ (1) | NZ540872A (es) |
OA (1) | OA12970A (es) |
PL (1) | PL377053A1 (es) |
RS (1) | RS20050450A (es) |
UA (1) | UA83648C2 (es) |
WO (1) | WO2004052366A1 (es) |
ZA (1) | ZA200505492B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
ATE469157T1 (de) * | 2003-10-21 | 2010-06-15 | Inspire Pharmaceuticals Inc | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation |
TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
MX2008002363A (es) * | 2005-08-17 | 2008-03-18 | Schering Corp | Ligandos novedosos de cinasa basados en quinolina de alta afinidad. |
DE102006020385A1 (de) * | 2006-04-28 | 2007-10-31 | Dade Behring Marburg Gmbh | Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen |
CL2007002920A1 (es) * | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
AR063518A1 (es) * | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
KR20100015886A (ko) * | 2007-04-23 | 2010-02-12 | 사노피-아벤티스 | P2y12 길항제로서의 퀴놀린-카복스아미드 유도체 |
MY148901A (en) | 2007-06-18 | 2013-06-14 | Sanofi Aventis | Pyrrole derivatives as p2y12 antagonists |
CA2706475C (en) | 2007-11-29 | 2016-05-03 | Actelion Pharmaceuticals Ltd | Phosphonic acid derivates and their use as p2y12 receptor antagonists |
AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
RU2011144763A (ru) * | 2009-04-08 | 2013-05-20 | Актелион Фармасьютиклз Лтд | 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины |
ES2469847T3 (es) | 2009-04-22 | 2014-06-20 | Actelion Pharmaceuticals Ltd. | Derivados de tiazol y su uso como antagonistas del receptor P2Y12 |
CN102304108B (zh) * | 2011-06-28 | 2013-11-06 | 中国药科大学 | 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途 |
CN104151235B (zh) * | 2014-08-07 | 2016-01-20 | 南阳师范学院 | 一种喹啉衍生物制备方法 |
BR112019004845A2 (pt) | 2016-09-22 | 2019-06-04 | Idorsia Pharmaceuticals Ltd | forma cristalina de cloridrato de éster butílico de ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidina-4 carbonil]-amino}-3-fosfono-propionil)-piperazina-1-carboxílico, processo para preparação de cloridrato de éster butílico de ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidina-4 carbonil]-amino}-3-fosfono-propionil)-piperazina-1-carboxílico, composição farmacêutica, e, éster butílico de ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidina-4 carbonil]-amino}-3-fosfono-propionil)-piperazina-1-carboxílico. |
AU2018234056B2 (en) | 2017-03-15 | 2023-05-25 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
CN112920181A (zh) * | 2021-01-29 | 2021-06-08 | 中国医科大学 | N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US60474A (en) * | 1866-12-18 | Pbtee chick | ||
GB1334705A (en) | 1970-06-19 | 1973-10-24 | Ici Ltd | Pharmaceutical compositions containing kynurenic acid derivatives |
US4258192A (en) * | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
AU8868991A (en) | 1990-11-15 | 1992-06-11 | Pentapharm Ag | Meta-substituted phenyl alanine derivatives |
CA2133761A1 (en) * | 1993-02-10 | 1994-08-18 | Jorg Sturzebecher | Piperazides of substituted phenylalanine derivates as thrombin inhibitors |
KR0173034B1 (ko) * | 1995-04-28 | 1999-03-30 | 성재갑 | 선택적 트롬빈 억제제 |
US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
-
2003
- 2003-12-09 PL PL377053A patent/PL377053A1/pl not_active Application Discontinuation
- 2003-12-09 AU AU2003297763A patent/AU2003297763A1/en not_active Abandoned
- 2003-12-09 ES ES03796831T patent/ES2348942T3/es not_active Expired - Lifetime
- 2003-12-09 WO PCT/US2003/039079 patent/WO2004052366A1/en active Application Filing
- 2003-12-09 US US10/731,815 patent/US7056923B2/en not_active Expired - Fee Related
- 2003-12-09 CA CA2507657A patent/CA2507657C/en not_active Expired - Fee Related
- 2003-12-09 KR KR1020057010688A patent/KR20050085580A/ko not_active Application Discontinuation
- 2003-12-09 MX MXPA05006302A patent/MXPA05006302A/es active IP Right Grant
- 2003-12-09 AP AP2005003363A patent/AP2005003363A0/xx unknown
- 2003-12-09 EA EA200500899A patent/EA200500899A1/ru unknown
- 2003-12-09 EP EP03796831A patent/EP1578423B1/en not_active Expired - Lifetime
- 2003-12-09 DE DE60333866T patent/DE60333866D1/de not_active Expired - Lifetime
- 2003-12-09 OA OA1200500175A patent/OA12970A/en unknown
- 2003-12-09 JP JP2004558607A patent/JP4662777B2/ja not_active Expired - Fee Related
- 2003-12-09 NZ NZ540872A patent/NZ540872A/en unknown
- 2003-12-09 BR BR0317222-8A patent/BR0317222A/pt not_active IP Right Cessation
- 2003-12-09 RS YUP-2005/0450A patent/RS20050450A/sr unknown
- 2003-12-09 UA UAA200506729A patent/UA83648C2/ru unknown
- 2003-12-09 CN CNA2003801096637A patent/CN1747732A/zh active Pending
- 2003-12-09 AT AT03796831T patent/ATE477800T1/de not_active IP Right Cessation
-
2005
- 2005-07-08 NO NO20053335A patent/NO20053335L/no not_active Application Discontinuation
- 2005-07-11 EC EC2005005912A patent/ECSP055912A/es unknown
-
2006
- 2006-01-12 US US11/331,621 patent/US7084142B2/en not_active Expired - Fee Related
- 2006-01-17 ZA ZA200505492A patent/ZA200505492B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004052366A1 (en) | 2004-06-24 |
ATE477800T1 (de) | 2010-09-15 |
CA2507657C (en) | 2011-05-31 |
JP2006511519A (ja) | 2006-04-06 |
KR20050085580A (ko) | 2005-08-29 |
NZ540872A (en) | 2007-08-31 |
US7084142B2 (en) | 2006-08-01 |
ZA200505492B (en) | 2006-03-29 |
EP1578423B1 (en) | 2010-08-18 |
RS20050450A (en) | 2007-08-03 |
EP1578423A1 (en) | 2005-09-28 |
WO2004052366A9 (en) | 2005-06-23 |
NO20053335L (no) | 2005-09-07 |
US20040138229A1 (en) | 2004-07-15 |
EA200500899A1 (ru) | 2006-02-24 |
MXPA05006302A (es) | 2005-08-29 |
BR0317222A (pt) | 2005-11-01 |
AP2005003363A0 (en) | 2005-09-30 |
US7056923B2 (en) | 2006-06-06 |
UA83648C2 (ru) | 2008-08-11 |
NO20053335D0 (no) | 2005-07-08 |
AU2003297763A1 (en) | 2004-06-30 |
JP4662777B2 (ja) | 2011-03-30 |
OA12970A (en) | 2006-10-13 |
US20060122188A1 (en) | 2006-06-08 |
CN1747732A (zh) | 2006-03-15 |
CA2507657A1 (en) | 2004-06-24 |
ES2348942T3 (es) | 2010-12-17 |
DE60333866D1 (de) | 2010-09-30 |
PL377053A1 (pl) | 2006-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055912A (es) | Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas | |
SE0202133D0 (sv) | Novel compounds | |
UY28572A1 (es) | Compuestos novedosos | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
ECSP067025A (es) | DERIVADOS DE TETRAAZABENZO [e] AZULENO Y SUS ANÁLOGOS | |
ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
UY27729A1 (es) | Inhibidores de quinasas. | |
EA200700189A1 (ru) | Производные хиназолина в качестве ингибиторов parp | |
ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
ATE547395T1 (de) | Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors | |
ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
CU23464B7 (es) | (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
UY28186A1 (es) | N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos. | |
NO20061845L (no) | Fenyl-piperazinderivater som modulatorer for muskarine reseptorer | |
ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
ATE365740T1 (de) | Substituierte pyrazolopyrimidine | |
IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
IL181271A0 (en) | Triazolophthalazine derivatives and pharmaceutical compositions containing the same | |
AR024138A1 (es) | Inhibidores de la proliferacion celular | |
SE0302139D0 (sv) | Novel compounds | |
NO20062900L (no) | Nye forbindelser | |
DK1641803T3 (da) | Thienopyrimidinderivater som kaliumkanalinhibitorer | |
SE0303541D0 (sv) | New compounds | |
PL374019A1 (en) | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |